Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication.

Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Sabine Kayser, Christoph Schliemann, Martin Kaufmann, Meinhard Kieser, Uwe Platzbecker, Carsten Müller-Tidow, Richard F Schlenk